Intended for healthcare professionals


NICE recommends flu drug for “at risk” patients

BMJ 2000; 321 doi: (Published 25 November 2000) Cite this as: BMJ 2000;321:1305
  1. Jason O'Neale Roach
  1. BMJ

    The National Institute for Clinical Excellence (NICE) recommended this week that zanamivir (Relenza) should be used to treat “at risk” adults when influenza is circulating in the community and if they present within 36 hours of developing symptoms. The institute defines such patients as those with chronic respiratory disease, significant cardiovascular disease, diabetes, or a compromised immune system, and those …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription